APLS · As filed with the SEC
Apellis Pharmaceuticals balance sheet, by quarter
The statement as Apellis Pharmaceuticals presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Condensed Consolidated Balance Sheets · USD
| USD | Q1 2026 Mar 31, 2026 | Q4 2025 Dec 31, 2025 | Q3 2025 Sep 30, 2025 | Q2 2025 Jun 30, 2025 | Q1 2025 Mar 31, 2025 | Q4 2024 Dec 31, 2024 | Q3 2024 Sep 30, 2024 | Q2 2024 Jun 30, 2024 |
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | 405,207,000 | 466,233,000 | 479,171,000 | 370,036,000 | 358,393,000 | 411,290,000 | 396,864,000 | 360,087,000 |
| Accounts receivable, net | 440,299,000 | 366,221,000 | 345,538,000 | 214,131,000 | 235,246,000 | 264,926,000 | 279,011,000 | 304,433,000 |
| Inventory | 131,408,000 | 142,556,000 | 122,819,000 | 121,000,000 | 82,468,000 | 81,404,000 | 121,058,000 | 152,772,000 |
| Prepaid assets | — | — | 31,560,000 | 29,171,000 | 37,104,000 | 18,368,000 | 23,809,000 | 28,971,000 |
| Prepaid and other current assets | 49,587,000 | 38,303,000 | — | — | — | — | — | — |
| Restricted cash | 1,520,000 | 1,527,000 | 1,430,000 | 1,430,000 | 1,434,000 | 1,322,000 | 1,373,000 | 1,339,000 |
| Other current assets | — | — | 10,158,000 | 19,842,000 | 13,073,000 | 11,644,000 | 11,782,000 | 12,372,000 |
| Total current assets | 1,028,021,000 | 1,014,840,000 | 990,676,000 | 755,610,000 | 727,718,000 | 788,954,000 | 833,897,000 | 859,974,000 |
| Non-current assets: | ||||||||
| Right-of-use assets | 18,945,000 | 18,195,000 | 19,720,000 | 14,637,000 | 15,251,000 | 16,083,000 | 17,060,000 | 16,321,000 |
| Property and equipment, net | 1,418,000 | 1,708,000 | 1,927,000 | 2,117,000 | 2,514,000 | 2,952,000 | 3,379,000 | 3,836,000 |
| Long-term inventory | 28,489,000 | 34,959,000 | 40,909,000 | 48,128,000 | 60,652,000 | 75,713,000 | 46,080,000 | 23,021,000 |
| Other assets | 5,659,000 | 5,555,000 | 5,491,000 | 898,000 | 1,150,000 | 1,349,000 | 1,450,000 | 1,330,000 |
| Total assets | 1,082,532,000 | 1,075,257,000 | 1,058,723,000 | 821,390,000 | 807,285,000 | 885,051,000 | 901,866,000 | 904,482,000 |
| Liabilities and Stockholders' Equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | 49,049,000 | 56,798,000 | 38,602,000 | 54,241,000 | 55,287,000 | 38,572,000 | 42,730,000 | 38,270,000 |
| Accrued expenses | 133,693,000 | 166,049,000 | 140,322,000 | 138,999,000 | 116,146,000 | 140,184,000 | 139,835,000 | 122,781,000 |
| Convertible senior notes | 93,744,000 | 93,662,000 | 93,581,000 | — | — | — | — | — |
| Current portion of lease liabilities | 6,962,000 | 7,087,000 | 7,022,000 | 7,419,000 | 6,944,000 | 6,753,000 | 6,792,000 | 6,214,000 |
| Deferred revenue | — | — | — | — | — | — | 1,903,000 | 1,903,000 |
| Total current liabilities | 283,448,000 | 323,596,000 | 279,527,000 | 200,659,000 | 178,377,000 | 185,509,000 | 191,260,000 | 169,168,000 |
| Long-term liabilities: | ||||||||
| Long-term credit facility | 362,243,000 | 361,664,000 | 361,091,000 | 360,535,000 | 360,001,000 | 359,489,000 | 358,982,000 | 364,025,000 |
| Convertible senior notes | — | 0 | 0 | 93,500,000 | 93,421,000 | 93,341,000 | 93,263,000 | 93,186,000 |
| Lease liabilities | 12,807,000 | 11,947,000 | 13,680,000 | 8,313,000 | 9,186,000 | 10,201,000 | 11,411,000 | 11,085,000 |
| Other liabilities | 9,111,000 | 7,903,000 | 3,257,000 | 2,078,000 | 2,084,000 | 7,972,000 | 9,829,000 | 2,691,000 |
| Total liabilities | 667,609,000 | 705,110,000 | 657,555,000 | 665,085,000 | 643,069,000 | 656,512,000 | 664,745,000 | 640,155,000 |
| Stockholders' equity: | ||||||||
| Preferred stock, $0.0001 par value; 10,000 shares authorized, and no shares issued and outstanding at March 31, 2026 and December 31, 2025 | 0 | 0 | 0 | 0 | — | 0 | 0 | 0 |
| Common stock, $0.0001 par value; 200,000 shares authorized at March 31, 2026 and December 31, 2025; 127,923 shares issued and outstanding at March 31, 2026, and 126,621 shares issued and outstanding at December 31, 2025 | 13,000 | 12,000 | 12,000 | 12,000 | 12,000 | 12,000 | 12,000 | 12,000 |
| Additional paid-in capital | 3,411,643,000 | 3,385,216,000 | 3,357,583,000 | 3,328,604,000 | 3,294,849,000 | 3,267,201,000 | 3,239,262,000 | 3,209,245,000 |
| Accumulated other comprehensive loss | (2,411,000) | (2,103,000) | (2,400,000) | (2,569,000) | (3,054,000) | (3,308,000) | (3,140,000) | (3,362,000) |
| Accumulated deficit | (2,994,322,000) | (3,012,978,000) | (2,954,027,000) | (3,169,742,000) | (3,127,591,000) | (3,035,366,000) | (2,999,013,000) | (2,941,568,000) |
| Total stockholders' equity | 414,923,000 | 370,147,000 | 401,168,000 | 156,305,000 | 164,216,000 | 228,539,000 | 237,121,000 | 264,327,000 |
| Total liabilities and stockholders' equity | 1,082,532,000 | 1,075,257,000 | 1,058,723,000 | 821,390,000 | 807,285,000 | 885,051,000 | 901,866,000 | 904,482,000 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.